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VE-cadherin is a component of endothelial cell-to-cell adherens junctions, and it has a key role in the main-
tenance of vascular integrity. During embryo development, VE-cadherin is required for the organization of a
stable vascular system, and in the adult it controls vascular permeability and inhibits unrestrained vascular
growth. Themechanisms of action of VE-cadherin are complex and include reshaping and organization of the
endothelial cell cytoskeleton and modulation of gene transcription. Here we review some of the most impor-
tant pathways through which VE-cadherin modulates vascular homeostasis and discuss the emerging con-
cepts in the overall biological role of this protein.Introduction
Endothelial cells form monolayers that cover the internal surface
of blood vessels and protect the tissues from noxious blood
components and inflammatory cells. The endothelial integrity is
maintained by a complex functional balance between multiple
cell activities that modulate the inhibitory activity of the vessel
wall to thrombosis or inflammatory reactions.
Endothelial cell-to-cell junctions have crucial roles in these
processes because they not only maintain intercellular adhe-
sion but also transfer intracellular signals that modulate contact
inhibition of cell growth, cell polarity, lumen formation, and in-
teractions with pericytes and smooth muscle cells (for review,
see Dejana et al., 2009). Therefore, conditions that disrupt
endothelial junctions might not only increase vascular perme-
ability by opening intercellular gaps but also change the
endothelial cell responses to their environment and to the sur-
rounding cells.
Endothelial adherens junctions have been studied extensively
by several groups (for reviews, see Dejana et al., 2009; Delva and
Kowalczyk, 2009; Komarova and Malik, 2010; Vestweber et al.,
2009). A schematic view of the multiple components that can
associate to adherens junctions is shown in Figure 1. The
‘‘basic’’ organization of adherens junctions is provided by
vascular endothelial cadherin (VE-cadherin), which is linked
through its cytoplasmic domain to p120-catenin and b-catenin
or plakoglobin (Figure 1) (Dejana and Vestweber, 2013).
The identified intracellular partners of VE-cadherin so far are
multiple, and it is likely that many more will be discovered in
the future (Table 1). The cytoplasmic domain of VE-cadherin
is highly homologous to that of classic cadherins such as
N-cadherin or E-cadherin and shares with them some intracel-
lular partners such as p120-catenin or b-catenin. An exception
is plakoglobin, which is commonly associated with desmosomes
in epithelial cells but can directly bind to VE-cadherin in endothe-
lial cells, which lack desmosomes (for review, see Bazzoni and
Dejana, 2004).
A systematic study of the different partners of VE-cadherin in
comparison with other members of the cadherin family is
missing. Some partners are specific to endothelial cells, suchDeas VE-PTP, PECAM, or VEGFR2, and are, as a consequence,
also specific for VE-cadherin.
However, themajority of themolecules listed in Table 1 are ex-
pressed also in other cell types and have the potential to interact
with other members of the cadherin family.
Considering the large number of putative partners of VE-
cadherin, it is tempting to speculate that these proteins can
assemble into different types of complexes, which would vary
according to their composition and function, the different vessels
and stages of development, and even within the same cell.
This Review will mainly focus on VE-cadherin and adherens
junction organization in endothelial cells to highlight the func-
tional activity of these molecules and their roles in the control
of vascular permeability and intracellular signaling. Some of the
relevant members of the cadherin complex that have been
identified and studied in other cell types will also be briefly
mentioned.
Cadherin Expression and Function in Endothelial Cells
At adherens junctions, adhesion is mediated by the cadherins,
which are calcium-dependent adhesion molecules. Endothelial
cells express VE-cadherin and N-cadherin to comparable levels,
although in most cases, only VE-cadherin is clustered at cell-to-
cell contacts, with N-cadherin excluded from these structures
(Navarro et al., 1998). This particular behavior of N-cadherin is
not endothelial-cell specific but is related to the functional and
structural features of these two cadherins. Cotransfection of
VE-cadherin with N-cadherin in Chinese hamster ovary (CHO)
cells prevents N-cadherin localization to the adherens junctions
(Navarro et al., 1998). A similar result was obtained upon
transfection of a VE-cadherin mutant that was truncated in the
cytoplasmic domain, which suggests that the extracellular
region of VE-cadherin, its residual cytoplasmic tail, or its trans-
membrane domain is responsible for N-cadherin exclusion
from the adherens junctions (Giampietro et al., 2012; Navarro
et al., 1998).
Regardless of the mechanism, these observations suggest
that VE-cadherin and N-cadherin have different functions in
endothelial cells. Because N-cadherin is expressed in severalvelopmental Cell 26, September 16, 2013 ª2013 Elsevier Inc. 441
Figure 1. Multiple Functions of Adherens
Junctions in Endothelial Cells
The organization of adherens junctions is provided
by VE-cadherin, which is linked through its cyto-
plasmic domain to p120-catenin, b-catenin, and
plakoglobin. These proteins assemble in diverse
complexes and have different functions. The in-
teractions of VE-cadherin with the growth factor
receptors VEGFR2, FGF-R1, and the TGFb-R
complex modulate their downstream signaling.
The cytoskeletal remodeling controlled by VE-
cadherin is through its indirect interaction with
various actin-binding proteins, such as a-catenin,
vinculin, a-actinin, eplin, and others. In addition,
the stability of the adherens junctions is regulated
by the clustering of VE-cadherin and its indirect
association with different partners, such as Tiam,
the CCM complex, and vinculin. Some phospha-
tases such as VE-PTP, DEP-1, PTP-m, Csk, and
SHP2 might also associate with VE-cadherin and,
directly or indirectly, decrease its phosphoryla-
tion and increase endothelial barrier function.
Conversely, phosphorylation of VE-cadherin by
Src or FAK, as well as the VE-cadherin interaction
with b-arrestin2, induces junction weakening. See
the text for more details.
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esting possibility is that N-cadherin promotes endothelial cell
adhesion and communication with other cells, such as pericytes
or astrocytes (Takeichi, 1988). This indicates that such interac-
tions are important in the elongation of vascular sprouts and in
the formation of the so-called neurovascular unit in the brain.
Indeed, direct contacts between endothelial cells and the under-
lying smooth muscle cells that define the myoendothelial junc-
tions have been described using electron microscopy, which
suggests that these myoendothelial junctions are required for
coordinated responses of the vessel walls to various stimuli
(Liebner et al., 2000).
Specific loss of N-cadherin in endothelial cells leads to early
embryonic death due to defects in vascular development. This
occurs earlier than pericyte or smooth muscle cell engagement
of the vasculature, which suggests that N-cadherin has a direct
role in endothelial cell function (Luo and Radice, 2005). In a
recent study, we showed that N-cadherin inhibits cell growth
and apoptosis in a way comparable to VE-cadherin (Giampietro
et al., 2012). However, while N-cadherin induced endothelial cell
motility, VE-cadherin had the opposite effect of limiting cell
movement. We also showed that VE-cadherin interacts with
the fibroblast growth factor (FGF) receptor and reduces the
receptor phosphorylation and signaling through coupling
with density-enhanced phosphatase-1 (DEP-1). Conversely,
N-cadherin maintains high FGF receptor activity in endothelial
cells and induces a set of genes that are crucial for cell migration
(Giampietro et al., 2012). Furthermore, we also showed that VE-
cadherin negatively controls both N-cadherin localization at
the adherens junctions and N-cadherin expression by limiting
p120-catenin availability and reducing b-catenin transcriptional
activity (Giampietro et al., 2012). Overall, these findings suggest
that any significant oscillation in VE-cadherin levels will increase
N-cadherin expression in the endothelium.
A tempting hypothesis is that these two cadherins contribute
to angiogenesis by acting at different levels. N-cadherin pro-
motes cell migration and contributes to vascular elongation,442 Developmental Cell 26, September 16, 2013 ª2013 Elsevier Inc.while VE-cadherin induces vascular quiescence by limiting
growth factor receptor signaling.
In some vessels, the endothelial cells express two other mem-
bers of the cadherin family, P-cadherin and T-cadherin (Bazzoni
and Dejana, 2004). T-cadherin is a glycosyl phosphatidylinositol-
anchored cell-surface glycoprotein, and it lacks the cytoplasmic
domain. As well as promoting cell-to-cell adhesion, T-cadherin
has a unique property: it can bind to the adipocyte-secreted hor-
mone adiponectin, which, in turn, has a cardioprotective activity
(Denzel et al., 2010) and promotes tumor angiogenesis (Denzel
et al., 2009).
VE-Cadherin and the Development of the Vascular
System in the Embryo
VE-cadherin is one of the first cell-specific markers to be ex-
pressed by endothelial cells during the development of the
embryo vasculature and embryonic stem cell differentiation to
endothelial cells in vitro (Breier et al., 1996; Vittet et al., 1996,
1997) (Figures 2A–2C). Using in situ hybridization in the mouse
embryo, VE-cadherin transcripts have been detected at very
early stages of vascular development (embryonic day 7.5
[E7.5]) in mesodermal cells of the yolk-sac mesenchyme (Fig-
ure 2A). At later embryonic stages, VE-cadherin transcripts
were present in vascular structures of all of the organs examined,
which included the ventricles of the heart, the inner cell lining of
the atrium, the dorsal aorta, and the intersomitic vessels and
capillaries entering the brain. This suggests that VE-cadherin is
needed for the correct organization of the vasculature and for
endothelial assembly (Breier et al., 1996).
The early expression of VE-cadherin in endothelial progenitors
in the embryo suggests that it contributes to endothelial differen-
tiation. However, in VE-cadherin null mouse embryos, someearly
endothelial-cell-specific markers are still expressed, indicating
that early endothelial cell differentiation may also occur in the
absence of VE-cadherin (Breier et al., 1996; Crosby et al., 2005).
Strilic et al. (2009) showed that VE-cadherin participates in the
establishment of correct endothelial cell polarity and lumen
Table 1. Functional Interactors of VE-Cadherin and Adherens Junctions
Interactors Function References
Junction Architecture
b-catenin junction architecture and signaling Takeichi, 1988; Clevers, 2006; Dejana, 2010
p120 VE-cadherin stabilization and signaling Reynolds and Carnahan, 2004; Xiao et al., 2007;
McCrea et al., 2009
plakoglobin junction architecture and signaling Lampugnani et al., 1995; Nottebaum et al., 2008
a-catenin, a-actinin, eplin, N-WASP cytoskeletal anchorage and organization Hartsock and Nelson, 2008; Knudsen et al., 1995;
Abe and Takeichi, 2008; Chervin-Pe´tinot et al., 2012;
Rajput et al., 2013
Junction Stability and Cytoskeleton Organization
Tiam activation of Rac, junction stability Lampugnani et al., 2002; Cain et al., 2010
Rap1, Raf1, MAGI junction stability and maturation Sakurai et al., 2006; Glading et al., 2007; Wimmer
et al., 2012
Phosphatases Junction Stability
VE-PTP VE-cadherin dephosphorylation, permeability
control, leukocyte diapedesis
Nottebaum et al., 2008; Nawroth et al., 2002;
Broermann et al., 2011
PTP1B, PTP2A, SHP2, DEP-1, RPTP-m permeability control Grinnell et al., 2010, 2012; Ukropec et al., 2000;
Ka´sa et al., 2013; Hatanaka et al., 2012; Lampugnani
et al., 2006; Orsenigo et al., 2012, Sui et al., 2005
Csk Src inactivation, inhibition of cell growth Baumeister et al., 2005
Cell Polarity
PAR3/PAR6/aPKC cell polarity, lumen formation Lampugnani et al., 2010; McCaffrey and Macara,
2012; Iden et al., 2006; Koh et al., 2008
CCM1/Krit1 cell polarity, junction stability Lampugnani et al., 2010; Glading et al., 2007
Growth Factor Receptors
VEGFR2 contact inhibition of cell growth, permeability
control
Nottebaum et al., 2008; Weis et al., 2004; Lampugnani
et al., 2006; Gavard and Gutkind, 2006
FGF-R cell motility and growth Murakami et al., 2008; Giampietro et al., 2012
TGFb-R inhibition of cell motility Rudini et al., 2008; Rezaei et al., 2012
Induction of Permeability
b-arrestin1, b-arrestin2, Caveolin1 junction permeability Gavard and Gutkind, 2006; Hebda et al., 2013;
Kronstein et al., 2012
Other Functions
PECAM mechanosensor Conway and Schwartz, 2012; Tzima et al., 2005
PI3 kinase, Akt, Shc signal transduction Taddei et al., 2008; Zanetti et al., 2002
Src, FAK increase in permeability Weis et al., 2004; Wallez et al., 2007; Chen et al., 2012
We report here some of the best-studied partners of VE-cadherin and adherens junctions. We apologize if, for space constraints, the table is not
exhaustive.
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development, endothelial cells adhere to each other, and the
CD34-sialomucins—moesin, F-actin, and nonmuscle myosin
II—localize at the endothelial cell-to-cell contacts to define the
luminal cell surface. VE-cadherin is required for this CD34-sialo-
mucin localization. This promotes the recruitment of moesin and
F-actin, which results in changes in endothelial shape and the
consequent lumen formation.
Some observations of vascular development of isolated
allantoises, which consist of all embryonic and extraembryonic
tissues and simulate the first steps of vasculogenesis, have also
underlined the crucial role of VE-cadherin in early vascular
organization. In this system, in the absence of VE-cadherin or
with a block of its extracellular domain by functional antibodies,
endothelial cells cannot organize into a functional vasculature.
A detailed analysis of vasculogenesis in this experimental sys-Detem has shown that VE-cadherin is not required for the early
stages of de novo blood vessel formation. However, VE-
cadherin is needed to prevent disassembly of nascent blood
vessels into disorganized endothelial aggregates (Figure 2D)
(Crosby et al., 2005). In zebrafish, it has been possible to
further dissect out the roles of VE-cadherin at different stages
of vascular development (Montero-Balaguer et al., 2009).
Although VE-cadherin does not regulate vascular patterning, it
is implicated in vascular connections and inhibition of sprouting
activity. These processes require stable cell-to-cell junctions,
which are defective in the absence of VE-cadherin. Of note,
an incomplete reduction of VE-cadherin expression also pre-
vents the formation of a stable vasculature, suggesting that
even a partial internalization or change in function of VE-
cadherin may strongly affect vascular stability (Montero-
Balaguer et al., 2009).velopmental Cell 26, September 16, 2013 ª2013 Elsevier Inc. 443
Figure 2. VE-Cadherin and the Development of the Vascular System in the Embryo
(A) Expression of VE-cadherin at day E7.5 of the mouse embryo and in situ hybridization of frozen sections with 35S-labeled antisense VE-cadherin RNA.
(a0) Parasagittal section of a day E7.5 mouse embryo in the maternal decidua. High levels of VE-cadherin transcripts were detected in the trophoblast, in blood
vessels of the maternal decidua, and in the yolk sac mesenchyme. (b0 ) High-magnification field of the framed region (white rectangle) containing the embryo
shown in (a0). C, chorion; MS, yolk sacmesenchyme; EC, embryonic ectoderm; EN, endoderm (outlined by arrowhead); D, decidua; E, embryo; EP, ectoplacental
cavity; EX, exocoelom. (c0) Dark-field image of (b0). Arrows (in b0 and c0) denote VE-cadherin signals in yolk sac mesenchyme. Scale bars, 100 mm (a0) and 25 mm
(b0 and c0). This research was originally published in Breier et al. (1996). Copyright the American Society of Hematology.
(B) VE-cadherin null mutation impairs organized, vascular-like structures in embryonic stem-cell-derived 11-day-old embryoid bodies. PECAM whole-mount
immunocytochemistry of representative wild-type (+/+, left), VE-cadherin mutant (+/, middle and/, right) embryoid bodies. Scale bar, 100 mm. This research
was originally published in Vittet et al. (1997). Copyright the National Academy of Sciences.
(C) Kinetics of endothelial marker expression in differentiating embryonic stem cells from days 3 to 7 by RT-PCR. Flk-l (VEGFR2) and PECAM gene expression are
rapidly (day 4) upregulated during embryonic stem cell differentiation, whereas VE-cadherin and tie-1 transcripts appear 1 day later (day 5). After day 5, all
transcript levels remained high and consistent. The negative control (no template) for each PCR reaction is also shown. This research was originally published in
Vittet et al. (1996). Copyright the American Society of Hematology.
(D) VE-cadherin null allantois explants fail to undergo normal vascular morphogenesis in culture. PECAM-immunolabeled allantois explants from 8.5 days
postcoitum VE-cadherin+/+ and VE-cadherin/ embryos after 18 hr of culture. The interconnected networks of PECAM cells in wild-type explants (+/+) are
absent in VE-cadherin null explants (/) and are replaced by isolated clusters of PECAM cells. Scale bars, 100 mm. This research was originally published in
Crosby et al. (2005). Copyright the American Society of Hematology.
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extensive experimental data (Lenard et al., 2013). In a fish model
wherein the vessels do not express functional VE-cadherin, the
early sprouting vessels failed to anastomose correctly. However,
VE-cadherin-deficient vascular sprouts can still recognize each
other and form connections, possibly through other adhesive
molecules that can promote homotypic adhesion. Interestingly,
these connections do not last, and the filopodia of the endothelial
tip cells of the sprouting vessels keep touching and retracting for
a relatively long period of time before a functional anastomosis is
created. Most importantly, in the normal vasculature, when tip
cells connect with each other and create a successful anasto-
mosis, they also stop forming filopodia. This important inhibitory444 Developmental Cell 26, September 16, 2013 ª2013 Elsevier Inc.process avoids uncontrolled sprouting and vascular branching.
When the tips of endothelial cells lack VE-cadherin expression,
they can still form anastomoses, as above, but they do not
stop forming filopodia. In other words, in the absence of VE-
cadherin, the cells do not sense the cell-to-cell contact, but
instead keep searching for other connections. These important
in vivo observations underline the ability of VE-cadherin to trans-
fer intracellular inhibitory signals to limit endothelial cell move-
ment and cytoskeletal rearrangement (Lenard et al., 2013).
Therefore, VE-cadherin appears to be an important factor in
mediating vascular stability. Indeed, it is required to maintain
the strength and duration of endothelial cell-to-cell interactions,
which allows the fusion of the vascular sprouts and the creation
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rectly transfers negative signals to switch the cells to a quiescent
state.
This concept was further supported by a study by Gaengel
et al. (2012), who used genetic approaches in both zebrafish
and mice. They showed that activation of sphingosine-1-phos-
phate receptor-1 (S1PR1), which is a receptor that recognizes
the blood-borne lipid sphingosine-1-phosphate, limits unre-
strained angiogenic sprouting and ectopic vessel branch forma-
tion. This effect is mediated by stabilization of VE-cadherin at
adherens junctions, which, in turn, contributes to limit vascular
endothelial growth factor receptor (VEGFR) signaling, and, as a
consequence, aberrant angiogenesis (Gaengel et al., 2012).
Furthermore, Jung et al. (2012) described the effect of laminar
blood flow in transducing signals through S1PR1 in endothelial
cells, which promotes vascular stability and suppresses ectopic
sprout formation. Interestingly, sphingosine-1-phosphate coloc-
alizes with VE-cadherin, which is a component of a mechano-
sensory complex together with platelet endothelial cell adhesion
molecule (PECAM) and VEGFR2, as discussed below (Hahn and
Schwartz, 2009; Tzima et al., 2005).
It is therefore likely that VE-cadherin is a downstream effector
of sphingosine-1-phosphate/S1PR1 signaling that acts by stabi-
lizing the vasculature and preventing unrestrained vascular
sprouting and angiogenesis.
VE-Cadherin and Intracellular Signaling
As previously described (for reviews, see Dejana and Giampie-
tro, 2012; Dejana and Vestweber, 2013; Vestweber et al.,
2009), in addition to promoting adhesion between endothelial
cells, VE-cadherin and adherens junctions can transfer intracel-
lular signals. This underlines the concept that adhesion is linked
to intracellular signaling and that, when endothelial cells come
into contact, they communicate with one another to build and
maintain the vascular organization.
The signaling network transduced by VE-cadherin is complex
and varies under different functional conditions and in growing or
resting vasculature (Dejana and Vestweber, 2013; Harris and
Nelson, 2010). As a general concept, the natural state of endo-
thelial cells in mature vessels is that of a confluent, restingmono-
layer, in which VE-cadherin is clustered at cell-to-cell contacts
and adherens junctions are correctly organized. Under these
conditions, signaling through VE-cadherin promotes vascular
stability, such as contact inhibition of growth, protection from
apoptosis, and control of endothelial permeability.
However, as discussed above, VE-cadherin contributes to key
and specific functional properties of endothelial cells as well dur-
ing angiogenesis. These include establishment of cell polarity,
formation of a correct lumen, vascular tubulogenesis (Lampug-
nani et al., 2010; Strilic et al., 2009), rearrangement of the cyto-
skeleton (Komarova and Malik, 2010), tight junction remodeling,
and gene transcription (Taddei et al., 2008). The complexity of
VE-cadherin signaling is highlighted by the long list of signaling
proteins that have been shown to be directly or indirectly asso-
ciated to VE-cadherin or to adherens junctions in the endothe-
lium (Figure 1 and Table1).
VE-cadherin molecules are expressed at high numbers on
endothelial cell membranes. Therefore, it is likely that VE-
cadherin also forms distinct complexes with different partnersDeon the same cell. These complexes might transfer different types
of signals to the cells, depending on the functional conditions.
Furthermore, it is conceivable that VE-cadherin association
with one or another mediator is reversible and can be temporally
and spatially regulated.
Inhibition of Cell Growth
Endothelial cells inhibit their growth and motility as soon as they
come into contact and have established cell-to-cell junctions.
This process is known as contact inhibition, and it is mediated
by the action of different signaling pathways.
Different molecules at adherens junctions contribute to this
quiescent state. In particular, VE-cadherin can interact and
cocluster with growth factor receptors and control their intracel-
lular signals (Dejana and Vestweber, 2013). More specifically,
VE-cadherin interacts with VEGFR2 and inhibits its downstream
proliferation signal through the signaling of extracellular-regu-
lated kinases 1 and 2 (ERK1 and ERK2) while maintaining or
increasing antiapoptotic signaling through protein kinase B
(PKB/Akt). The cytoplasmic domain of VE-cadherin and expres-
sion of b-catenin are required for association with the VEGFR2
(Lampugnani et al., 2002). When VEGFR2 is bound to VE-
cadherin, it is retained at the cell membrane, where it is quickly
dephosphorylated by phosphatases on specific tyrosine resi-
dues and, in particular, by DEP-1 (Lampugnani et al., 2006). As
described for other growth factor receptors (Le Roy and Wrana,
2005), internalization of VEGFR2 can strongly influence its
signaling. VEGFR2 can be targeted to degradation, to recycling
to themembrane, or tomaintenance of signaling activity from the
endosomal compartments.
In confluent resting endothelial cells, VE-cadherin association
to VEGFR2 is long lasting and maintains VEGFR2 dephosphory-
lation and the cells in a quiescent state (Hayashi et al., 2013).
During angiogenesis, VEGF stimulates the sprouting of new ves-
sels by inducing VEGFR2 activity in the tip cells, while in the stalk
cells of the sprout, VEGFR2 activity is downregulated. It has
been reported that VEGFR2 in stalk cells is dephosphorylated
by VE-PTP at endothelial junctions. VE-PTP inactivation leads
to excess VEGFR2 activity, increased tyrosine phosphorylation
of VE-cadherin, and loss of cell polarity and lumen formation
(Hayashi et al., 2013).
Other molecules can also act in similar ways. A recent report
showed that in vivo in retinal angiogenesis, Disabled 2 (Dab2)
and the cell polarity factor partitioning defective protein 3
(PAR3) mediate VEGFR2 endocytosis by clathrin-coated vesi-
cles. Atypical protein kinase C (aPKC) has been shown to inhibit
VEGFR2 endocytosis by inhibition of Deb2 by reducing its inter-
action with VEGFR2 (Nakayama et al., 2013). VE-cadherin has
been shown to codistribute and associate with PAR3, and the
activation of aPKC is inhibited in the absence of VE-cadherin
(Iden et al., 2006; Lampugnani et al., 2010). These indirect obser-
vations suggest that VE-cadherin might modulate VEGFR2
signaling and internalization, contributing to Dab2/PAR3 inhibi-
tion and to aPKC activation.
Ephrin B2 is the transmembrane ligand of EphB receptors, and
it can also promote VEGFR2 endocytosis and downstream
signaling. Whether ephrin B2 may interact with VE-cadherin
in this process is unknown (Nakayama et al., 2013; Wang
et al., 2010). Similarly, synectin is involved in the trafficking ofvelopmental Cell 26, September 16, 2013 ª2013 Elsevier Inc. 445
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VEGFR2-endosome movement is delayed and VEGFR2 is
dephosphorylated by protein tyrosine phosphatase 1b (PTP1b)
(Lanahan et al., 2010). Interestingly, PTP1b also stabilizes cell-
to-cell adhesions by reducing tyrosine phosphorylation of VE-
cadherin (Nakamura et al., 2008). Thus, the same phosphatase
might contribute both to the reduction in VEGF signaling and
to junction stability.
A recent paper added more information to this picture. It was
found that neuropilin-1 could associate to VEGFR2 and synectin
via a PDZ-containing domain (Lanahan et al., 2013). Neuropilin-1
is required for a rapid internalization of the receptor in endo-
somes. In the absence of neuropilin-1 cytoplasmic domain, the
receptor remains at the cell membrane and is rapidly dephos-
phorylated. As discussed above, a similar phenomenon occurs
in absence of VE-cadherin (Lampugnani et al., 2006), but
whether VE-cadherin can associate and influence the structure
and function of neuropilin-1, synectin, and VEGFR2 complex is
an attractive but still unknown possibility.
Overall, as for other growth factor receptors, VEGFR2 internal-
ization and trafficking depends on coreceptors. VE-cadherin,
similarly to other cofactors such as neuropilin-1, synectin,
ephrin-B2, and protein phosphatases, coordinates VEGFR2
activation and internalization, strongly influencing the intensity
and duration of signaling.
Other Pathways that Can Contribute to Inhibition of Cell
Growth
VE-cadherin was shown to be associated with c-Src and C-ter-
minal Src kinase (Csk), a negative regulator of Src activation
(Baumeister et al., 2005) and inhibitor of cell growth. The associ-
ation with Csk requires phosphorylation of tyrosine 685 (Y685) in
the VE-cadherin tail. Addition of VEGF to cultured endothelial
cells stimulates Csk release from VE-cadherin by recruiting the
SH2-domain-containing tyrosine phosphatase 2 (SHP2) to the
VE-cadherin signaling complex, which leads to an increase in
c-Src activation. Inhibition of VE-cadherin and SHP2 enhances
ERK1/2 activation in response to VEGF (Ha et al., 2008). These
findings reveal a novel role for VE-cadherin in the modulation
of c-Src activation in VEGF signaling, thus providing new insights
into the importance of VE-cadherin in VEGF signaling and
vascular function (Ha et al., 2008).
Transcriptional Signaling
There is evidence that many VE-cadherin binding partners, such
as b-catenin, p120-catenin, and plakoglobin, can also translo-
cate to the nucleus to regulate transcription. This supports the
idea that VE-cadherin can signal indirectly by recruiting these
molecules to the membrane and thus inhibiting their nuclear
signaling.
The most-studied cadherin partner is probably b-catenin,
which is one of the key players in canonical Wnt signaling
(Clevers, 2006; Clevers and Nusse, 2012). It is constitutively
bound to VE-cadherin. When b-catenin is free in the cyto-
plasm, it is quickly inactivated by phosphorylation and
ubiquitination by a protein complex that includes axin and
adenomatous polyposis coli (APC). However, when the amount
of VE-cadherin expressed is reduced in endothelial cells, or
when endothelial cells are activated by Wnt, b-catenin can446 Developmental Cell 26, September 16, 2013 ª2013 Elsevier Inc.translocate to the nucleus and modulate gene transcription
(Dejana, 2010).
Although nuclear b-catenin does not belong to the cadherin-
associated pool in Drosophila and Xenopus (Funayama et al.,
1995; Peifer et al., 1994), in other cell types, and in particular in
the endothelium, cadherin expression and b-catenin signaling
are interrelated (for reviews, see Jeanes et al., 2008; McEwen
et al., 2012). As discussed above, VE-cadherin might act as a
stoichiometric inhibitor of b-catenin by retaining the molecule
at the cell membrane. Alternatively, cadherins might act by
modulation of the rate of b-catenin destruction. This is supported
by the observation that the phosphodestruction complex for
b-catenin is localized at cell-to-cell contacts in nonendothelial
cell lines (Maher et al., 2009). An interesting hypothesis is that
the membrane-associated destruction complex is ‘‘tunable’’ by
the cadherins, which may control, in this way, the amount of
b-catenin degradation and nuclear signaling (Maher et al.,
2009; McEwen et al., 2012)
In the nucleus, b-catenin interacts with members of the
lymphoid enhancer factor/T cell factor (LEF/TCF) protein family
(Clevers and Nusse, 2012) and also with other transcription fac-
tors, such as Forkhead box protein O1 (FoxO1), hypoxia-induc-
ible factor (HIF), Smads, and others (for review, see Dejana,
2010).
As well as controlling b-catenin signaling, VE-cadherin might
also bind other armadillo proteins that have transcriptional activ-
ity, such as p120-catenin and plakoglobin (Reynolds, 2007). At
the transcriptional level, p120-catenin associates with the
transcriptional repressor Kaiso, which it displaces from specific
promoters, to allow activation of the corresponding genes (for
review, see McCrea et al., 2009). The transcriptional activity
of plakoglobin has not been studied as extensively as that of
b-catenin (McCrea et al., 2009). Some reports have shown that
plakoglobin can bind to TCF/LEF transcription factors and
have transcriptional activity; this is, however, contradicted by
other reports, which have shown that the plakoglobin-TCF com-
plex cannot bind to DNA (McCrea et al., 2009; Zhurinsky et al.,
2000).
Another transcription factor modulated by E-cadherin and
adherens junction organization is Yes-associated protein 1
(YAP). When this factor translocates to the nucleus and associ-
ates with the DNA-binding factors TEA domain family member-1
(TEAD) or transcriptional enhancer factor (TEF), this activates
genes that promote cell proliferation. When the cells are
confluent, YAP is phosphorylated and excluded from the
nucleus, thus limiting cell proliferation. The mechanism through
which the cadherin complex restrains YAP signaling remains
poorly understood, although a-catenin appears to be indirectly
or directly implicated (Kim et al., 2011; Schlegelmilch et al.,
2011; Silvis et al., 2011).
Taken together, the data discussed above imply that the
cadherins, and VE-cadherin in particular, can either repress or
stimulate gene transcription. An interesting question is which
type of transcriptional programmight be induced by VE-cadherin
expression and clustering. Intuitively, it would be expected that
VE-cadherin activates and maintains the functions related to
endothelial cell quiescence and vascular stability.
Gene profile analysis has shown that several genes impli-
cated in the inhibition of cell proliferation and apoptosis are
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A number of these genes, and in particular the tight-junction
adhesive protein claudin 5, are induced by a complex mecha-
nism that involves VE-cadherin activation of phosphoinositide
3-kinase (PI3K) and Akt. Active Akt in turn phosphorylates and in-
hibits FoxO1. The FoxO1 transcription factor forms a complex
with nuclear b-catenin, which represses claudin 5 (Taddei
et al., 2008). In the presence of VE-cadherin, this repression is
released and claudin 5 is upregulated, thus promoting junction
tightening. Other vascular stability genes might follow the
same mechanisms of regulation by VE-cadherin (Taddei et al.,
2008).
VE-Cadherin and Actin Cytoskeletal Remodeling
The anchorage of junctional proteins to the cytoskeleton has a
crucial role in the control of endothelial cell shape, movement,
and permeability. VE-cadherin binds b-catenin and plakoglobin
through its cytoplasmic tail, and these in turn can bind a-catenin,
which regulates the actin cytoskeleton, and therefore cell shape
and motility. How cadherin-catenin complexes interact with the
actin cytoskeleton is still a matter of debate, as direct interaction
of the cadherin–b-catenin–a-catenin complex with actin fila-
ments has been questioned (Hartsock and Nelson, 2008). In its
monomeric state, a-catenin binds b-catenin that is coupled to
cadherin, but it does not bind actin (Yamada et al., 2005). How-
ever, homodimeric a-catenin binds actin, and not b-catenin, and
promotes the bundling of actin filaments (Drees et al., 2005).
Thus, the binding of a-catenin to the cadherin complex might
negatively regulate the a-catenin action on actin polymerization
(Hartsock and Nelson, 2008). Various actin-binding proteins,
such as a-actinin (Knudsen et al., 1995; Nieset et al., 1997), vin-
culin (Watabe-Uchida et al., 1998; Weiss et al., 1998), and Eplin
(Abe and Takeichi, 2008), can also bind a-catenin. Of these
candidate linker molecules, Eplin has been shown to directly
link the E-cadherin–b-catenin–a-catenin complex with actin
(Abe and Takeichi, 2008; Chervin-Pe´tinot et al., 2012).
A recent study described so-called focal adherens junctions
between endothelial cells (Huveneers et al., 2012). These junc-
tions were defined as attachment sites for radial F-actin bundles
and sites of junction remodeling. They were formed upon stimu-
lation with junction-challenging agents, such as thrombin. Vincu-
lin associates with these structures in a way that is dependent on
the actomyosin contractility and on the exposure of a specific
vinculin-binding a-catenin domain. As a consequence of this
force-dependent binding of vinculin, the mechanical stability of
the focal adherens junctions was reinforced, and these endothe-
lial junctions were prevented from opening (Huveneers et al.,
2012).
Endothelial cells appear to ‘‘sense’’ changes in the shear
forces and respond by the reshaping of their cytoskeleton,
which, in turn, alters the tension forces on the junction proteins.
The VE-cadherin–catenins complex has a role in the transduc-
tion of the mechanical forces that shape endothelial cells
exposed to blood pressure and shear stress. VE-cadherin can
directly transduce themechanical forces to form amechanosen-
sor complex through its coupling to the junctional protein
PECAM and VEGFR2 (Conway et al., 2013; Tzima et al., 2005).
This complex transfers signals that can modulate Src and other
intracellular signals. These responses are needed for optimalDevascular homeostasis, to maintain the correct endothelial cell
attachment to the matrix and to regulate the blood flow. Impor-
tantly, the mechanosensor complex does not require adhesion
and clustering of VE-cadherin or PECAM at adherens junctions
because it is also active in sparsely spread, nonconfluent, endo-
thelial cells (Tzima et al., 2005). Furthermore, the signal is also
transferred in the absence of VEGF, which suggests the activa-
tion of VEGFR2 independent of its ligand. This supports the
concept that this particular mechanosensor complex can act
independently of adhesion or its localization at adherens junc-
tions. Thus, when VE-cadherin is associated with this particular
complex, it has a specific functional role that has never been
described previously for other members of the cadherin family.
VE-Cadherin, the Vascular Barrier, and Small GTPases
Despites its other functions, the best-studied role of VE-cadherin
is to promote homotypic endothelial cell-to–cell adhesion, which
contributes to the maintenance of vascular integrity. When junc-
tions are disrupted, the permeability is increased and the
vascular integrity is altered. This intuitive process, however,
appears to be complex, and it is influenced by several signaling
processes. In the present Review, we mostly focus on VE-
cadherin and vascular permeability to solutes, and we do not
discuss in detail permeability to leukocytes because other excel-
lent reviews are available on this topic (for reviews, see Engel-
hardt and Wolburg, 2004; Vestweber et al., 2009).
It has been shown (for reviews, see Beckers et al., 2010; God-
dard and Iruela-Arispe, 2013; Spindler et al., 2010) that different
members of the Rho GTPase family, such as Ras homolog gene
family, member A (RhoA), Ras-related C3 botulinum toxin sub-
strate 1 (Rac1), cell division control protein 42 homolog
(Cdc42), and Ras-related protein-1 small GTPase (Rap1),
contribute to the fine-tuning of vascular permeability under
both physiological and pathological conditions. Indeed, changes
in their activities are associated with the regulation of endothelial
barrier homeostasis, as well as with the disruption or reinforce-
ment of the barrier integrity, according to the context in which
they are activated (Komarova and Malik, 2010; Spindler et al.,
2010; van Nieuw Amerongen et al., 2007).
Rac1 and Cdc42 are generally thought to spatially control the
formation of filopodia and lamellipodia, which favors barrier
improvement, whereas RhoA is mainly involved in the organiza-
tion of stress fibers during cell contraction and also impairs
barrier integrity (Beckers et al., 2010; Spindler et al., 2010;
Wojciak-Stothard and Ridley, 2002). However, recent studies
have highlighted a more complex involvement of these small
GTPases in positive and negative regulation of the endothelial
barrier (Beckers et al., 2010).
Under resting conditions in endothelial cells (Figure 3A), VE-
cadherin regulates adherens junction stability and Rho GTPase
activation through interactions with p120-catenin and other
molecules. It was demonstrated previously that VE-cadherin
clustering increases the concentration of Tiam1, which is a
guanine nucleotide exchange factor (GEF) for Rac1, and p21-
activated kinase (PAK), which is a Rac effector, in the membrane
compartment, thus enhancing Rac1 activation (Lampugnani
et al., 2002). Similarly, the levels of active Cdc42 are elevated
in VE-cadherin-overexpressing endothelial cells (Kouklis et al.,
2003). Moreover, p120-catenin binding to VE-cadherin activatesvelopmental Cell 26, September 16, 2013 ª2013 Elsevier Inc. 447
Figure 3. Model for Regulation of Endothelial Barrier Function by Small GTPases
(A) Resting conditions: VE-cadherin expression and clustering may activate the small GTPase Rac1 and Cdc42 through Tiam. Rac1 increases endothelial barrier
function by stabilizing adherens junctions and inhibiting RhoA, which in turn decreases actomyosin contractility. Rap1 stabilizes cell-to-cell junctions and binds to
adherens junctions indirectly through Krit1.
(B) Permeability increasing agents: several barrier-destabilizing mediators, such as thrombin and VEGF, can induce transient and sustained increases in vascular
permeability throughmodulation of the activity of different small GTPases. Thrombin leads to impaired cAMP signaling, which causes both Rap1 inactivation and
activation of RhoA. VEGF increases permeability through different pathways (1) by Rac1 activation, ROS generation, and VE-cadherin endocytosis and (2) by
activation of the RhoA/Rho kinase pathway. See text for details and further discussion.
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Noren et al., 2000; Schuebel et al., 1998). The activated state of
these GTPases is maintained by IQ-motif-containing, GTPase-
activating protein 1 (IQGAP1), which inhibits their intrinsic
GTPase activity (Hart et al., 1996). However, Rac1 activates
different downstream targets, such as PAK and p190Rho-
GTPase activating protein (p190RhoGAP), which in turn inhibits
RhoA (Herbrand and Ahmadian, 2006; Wildenberg et al., 2006).
Therefore, under resting conditions, Rac1 activation stabilizes
adherens junctions and promotes endothelial barrier properties.
Conversely, in unperturbed endothelium, a basal Rho kinase
activity is essential for endothelial cell junction maintenance
and is necessary for the correct recruitment of VE-cadherin to
adherens junctions (van Nieuw Amerongen et al., 2007). A
more detailed analysis of endothelial dynamics has revealed
that even under resting conditions, adherens junctions are
continuously remodeled, which generates many tiny interendo-
thelial gaps that appear and disappear spontaneously. In this
context, RhoA activation occurs prior to gap closure, which sug-
gests a novel role for RhoA in the maintenance of endothelial
integrity (Szulcek et al., 2013).
Although there have been extensive investigations into RhoA
and Rac1 signaling in the control of basal endothelial functions,
the role of Rap1 under resting conditions is still largely unknown.
Both GAPs, such as RapGAP, and GEFs, such as exchange pro-
teins activated by cyclic AMP (cAMP) (Epac1) and PDZ-GEF,
have been proposed to regulate Rap1 in endothelial cells (Cullere
et al., 2005; Kooistra et al., 2005). Recently, it was demonstrated
(Pannekoek et al., 2011) that under resting conditions, Rap1
activity is mainly under the control of PDZ-GEF to maintain basal
endothelial barrier functions. Although the triggers responsible
for PDZ-GEF activation are still unclear, Epac1 activation is448 Developmental Cell 26, September 16, 2013 ª2013 Elsevier Inc.mediated by elevated levels of the second messenger cAMP
(Pannekoek et al., 2011). In this context, Epac-Rap1 signaling
stabilizes VE-cadherin at adherens junctions and induces actin
cytoskeleton rearrangements. These changes include disruption
of the radial stress fibers and induction of cortical actin bundles,
with the consequent switch from motile and discontinuous to
linear and stable junctions (Cullere et al., 2005; Fukuhara et al.,
2005; Noda et al., 2010; Sakurai et al., 2006).
Recently, the Rap1 effector Krev interaction trapped protein-
1/cerebral cavernous malformation 1 (Krit-1/CCM1) protein has
been proposed to be involved in Rap1-mediated regulation of
Rho signaling (Glading et al., 2007; Glading and Ginsberg,
2010; Stockton et al., 2010). Furthermore, through activation of
the common binding partner Rho GTPase-activating protein 29
(ArhGAP29), two other Rap1 effectors, Ras-interacting protein
1 (Rasip1) and Ras-association and dilute domain-containing
protein (Radil), cooperate to inhibit Rho-mediated stress fiber
formation and induce junctional tightening by reducing the
actomyosin-induced tension (Post et al., 2013).
Several barrier-destabilizing mediators, such as thrombin and
VEGF, can induce transient and sustained increases in vascular
permeability through modulation of the activity of different small
GTPases (Figure 3B). Several reports have shown fast and tran-
sient increases in RhoA activity upon thrombin stimulation
(Birukova et al., 2004; van Nieuw Amerongen et al., 2008). One
of the underlying mechanisms is Rho-kinase-mediated inactiva-
tion of myosin light chain (MLC) phosphatase, which leads to
increased MLC phosphorylation and actin-myosin contractility
(Essler et al., 1998; van NieuwAmerongen et al., 2000). Thrombin
increases RhoA activity along stress fibers and at cell margins
both in vitro and in vivo, thus destabilizing vascular integrity
(Szulcek et al., 2013). At the same time, thrombin-mediated
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through a reduction in cAMP levels, which in turn results in inhi-
bition of both the RapGEF Epac and Rap1 (Birukova et al., 2008).
This weakens the junctional complex and results in enhanced
vascular permeability. VEGF-mediated Rho GTPase activation
appears more restricted to a direct effect on the disruption of
adherens junctions. VEGF stimulation of endothelial cells acti-
vates Src, which stimulates Vav2, Rac1, and its downstream
effector PAK1. In turn, PAK1 phosphorylates a serine residue
in the cytoplasmic tail of VE-cadherin, thereby promoting its
endocytosis and increasing the vascular permeability (Gavard
and Gutkind, 2006). VEGF-induced Rac1 activation also pro-
motes the generation of reactive oxygen species (ROS). ROS
production is essential for Rac1/p190RhoGAP-induced downre-
gulation of RhoA (Nimnual et al., 2003).
Another level of regulation of small GTPase activity is the
different localization of GAPs and GEFs. VEGF promotes
displacement of the RhoA-specific GEF Syx from cell junctions,
thereby promoting junction disassembly (Ngok et al., 2012).
Conversely, treatment of endothelial cells with the vascular
normalizing agent angiopoietin1 maintains Syx at the adherens
junctions. This results in localized activation of RhoA and its
effector mDia, which in turn induces adherens junction stabiliza-
tion and prevents VEGF-induced permeability (Gavard et al.,
2008; Ngok et al., 2012). Furthermore, other reports have shown
that treatments of endothelial cells with vascular-protective
agents, such as the phospholipid 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphorylcholine (OxPAPC), promotes the
recruitment of p190RhoGAP to adherens junctions and its bind-
ing to p120-catenin, which leads to enhancement of the endo-
thelial barrier through the reduction of RhoA activity and the
increase in Rac1 signaling (Birukova et al., 2011; Zebda et al.,
2013). These findings suggest that precise spatial and temporal
regulation of the activity of Rho family GTPases and related pro-
teins is a strict requirement for the maintenance of endothelial
barrier integrity.
When all of these data are taken together, some of the
reported findings in vitro and in vivo appear contradictory. How-
ever, there are different explanations that can reconcile these
conflicting data. It is likely that the mechanisms that regulate
endothelial permeability in vitro might differ from the in vivo
setting.Most of the experimental evidence regarding the involve-
ment of the small GTPases in the control of endothelial barrier
function derives from cell-culture studies. Cultured endothelial
cells show more pronounced features than their in vivo counter-
parts. These cultured cells have a more contractile phenotype
and enhanced stress fiber formation, compared with intact
microvessels, which reflects the situation of inflammatory condi-
tions. In addition, it is possible that endothelial cells in culture are
more susceptible to contractile stimuli, because they migrate
and divide to generate a confluent monolayer that resembles
the cellular organization of blood vessels. This makes the junc-
tions of cultured cells relatively immature, and the resulting
endothelial barrier is less stable than under in vivo conditions.
In addition, endothelial cells are constantly exposed to shear
stress and mechanical forces in vivo, whereas most in vitro
studies are performed under static conditions. In conclusion,
in vitro data of the small GTPases and endothelial barrier regula-
tion need to be interpreted while taking into account both theDecellular background (e.g., microvascular-derived and macrovas-
cular-derived endothelial cells) and the results obtained in vivo.
In Vivo Modulation of Endothelial Barrier Function
Under in vitro and in vivo conditions, it is important to bear in
mind that adherens junctions are not static, but are dynamic
structures that continuously lose and gain cadherins. The orga-
nization and disorganization of adherens junctions are regulated
by a complex network of intracellular signaling pathways and by
the cytoskeleton (as described above). The complexity and
diversity of these pathways might reflect the multiple physiolog-
ical needs of endothelial cells and the type of responses to
permeability-increasing agents.
A common concept is that permeability-increasing agents act
by inducing VE-cadherin internalization and thereby reducing the
amount of VE-cadherin at adherens junctions and disrupting the
endothelial cell barrier.
VE-cadherin phosphorylation in Ser665 has been implicated in
the increase in permeability induced by VEGF. Phosphorylated
VE-cadherin associates with b-arrestin2 and is internalized
through clathrin-coated vesicles (Gavard and Gutkind, 2006).
Src-induced VE-cadherin phosphorylation on tyrosine also
appears to be required for an increase in permeability and VE-
cadherin internalization (Gavard et al., 2008; Orsenigo et al.,
2012; Weis et al., 2004), and Src inhibitors are among the most
potent inhibitors of permeability, both in vitro and in vivo. How-
ever, the precise mechanisms through which Src exerts its
action are far from being completely clear. In vitro studies have
shown that phosphorylation of VE-cadherin by Src is not enough
to increase endothelial permeability (Adam et al., 2010). Accord-
ingly, a recent study by our group (Orsenigo et al., 2012) showed
that in vivo, under resting conditions, VE-cadherin is phosphor-
ylated on tyrosine in the veins, but not in the arteries. VE-
cadherin phosphorylation is mediated by a specific pool of Src
that is localized at intercellular junctions. Treatment of mice
with permeability-increasing agents induces the specific inter-
nalization of phosphorylated VE-cadherin. Src-mediated VE-
cadherin phosphorylation acts as a ‘‘priming’’ mechanism,which
creates a dynamic state of the protein, which then becomes
more sensitive to internalization. Src therefore appears to be
required, but not sufficient, for VE-cadherin internalization.
P120-catenin dissociation from the VE-cadherin intracellular
tail is also recognized as a way through which cadherin is desta-
bilized at adherens junctions such that it is probably degraded
(Oas et al., 2010). Recently, a specific motif was defined in the
VE-cadherin tail that is required for VE-cadherin internalization
and p120 binding (Nanes et al., 2012). Mutations in this region
cause uncoupling of p120 and inhibition of internalization, which
strongly and selectively affects cell migration (Nanes et al.,
2012). However, the effect of the mutant on endothelial perme-
ability was not reported. A knockin model of this mutant in vivo
might help to understand the importance of this VE-cadherin
tail motif on its different vascular functions.
Another important mediator of endothelial permeability is focal
adhesion kinase (FAK). This kinase was originally found to coloc-
alize with integrins at focal contacts and to modulate cell adhe-
sion andmigration. Genetic and pharmacologic inhibition of FAK
prevents VEGF-induced endothelial permeability. VEGF activa-
tion of endothelial cells leads to the rapid binding of FAK tovelopmental Cell 26, September 16, 2013 ª2013 Elsevier Inc. 449
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dismantling of adherens junctions (Chen et al., 2012).
As discussed above, another important aspect in the control
of permeability by VE-cadherin is its association with the actin
cytoskeleton. A VE-cadherin a-catenin fusion construct has
been knocked in in mice (Schulte et al., 2011). This mutant
protein interacts more effectively with actin, and the vascula-
ture is resistant to the increase in permeability induced by his-
tamine or VEGF or to leukocyte transmigration. This strongly
suggests that a stable interaction with the actin cytoskeleton
might stabilize endothelial cell junctions and reduce their
dynamic opening.
Recently, it was shown that VE-cadherin also modulates the
microtubule cytoskeleton through the activation of End-binding
protein 3 (EB3). This process has an important role not only in
adherens junction assembly, but also in the modulation of
vascular permeability (Komarova et al., 2012)
Many other kinases and phosphatases have been shown to
interact with and modulate phosphorylation of VE-cadherin
and its partners and to modulate adherens junction strength
(for review, see Dejana and Vestweber, 2013; for details, see
Figure 1 and Table 1). Of particular importance is the association
of VE-cadherin with the phosphatase VE-PTP. The dissociation
of VE-PTP from VE-cadherin is triggered by endotoxin, VEGF,
and the binding of leukocytes to endothelial cells in vitro and
in vivo, suggesting that this dissociation is a prerequisite for
the destabilization of endothelial cell contacts (Broermann
et al., 2011; Vockel and Vestweber, 2013).
Overall, the complexity and redundancy of the intracellular
mechanisms that modulate adherens junction organization is
such that it is difficult, if not impossible, to draw a unique
picture.
Although rapid internalization and turnover of VE-cadherin is
associated with increases in endothelial permeability, this
process might not explain all of the steps of adherens junction
disassembly and barrier disruption. For instance, the amount
of VE-cadherin internalized upon stimulation with permeability-
increasing agents is relatively small, and, at least in vivo, this is
not always accompanied by a diffuse disorganization of adhe-
rens junction proteins from cell-to-cell contacts (Orsenigo
et al., 2012). It is possible that the permeability is also increased
when VE-cadherin and adherens junctions undergo relatively
subtle changes, which do not necessarily imply an obvious
opening of gaps between the endothelial cells, but rather only
subtle modifications of the junction architecture.
It is also probable that disruption of VE-cadherin clusters
leads to diffusion of VE-cadherin onto the cell membrane, which
is not necessarily coupled to internalization. Moreover, junction
reassembly is based on complex interactions between the
VE-cadherin ectodomain, which promotes its clustering at
intercellular contacts, and the reorganization of mature and
stable junctions. This process coincides with actin and tubulin
reorganization. Inactivation of actin polymerization or actomy-
osin contractility alters adherens junction formation. All of this
evidence suggests that the cytoskeleton regulates VE-cadherin
clustering and, conversely, that VE-cadherin reciprocally regu-
lates cytoskeletal organization and barrier integrity. However,
the molecular mechanisms through which all this occurs still
remain elusive.450 Developmental Cell 26, September 16, 2013 ª2013 Elsevier Inc.Concluding Remarks
As described here, the complexity of the organization of adhe-
rens junctions in the endothelium and the signaling pathways
that they can trigger is extremely high. Through these structures,
endothelial cells maintain continuous communication with each
other and can ‘‘sense’’ the blood flow and adapt their cytoskel-
eton accordingly.
Most of our knowledge about adherens junction and VE-
cadherin organization comes from studies performed on
cultured cells that are frequently derived from large vessels. In
contrast, endothelial cell responses in vivo vary profoundly in
different types of vessels and organs. For instance, endothelial
cells in postcapillary venules have poor control of the perme-
ability, which allows the dynamic passage of fluids and circu-
lating cells from the blood into the underlying tissue and vice
versa. Conversely, endothelial cells in brain microcirculation or
in large arteries apply tight control of permeability to protect
the tissues from undesired infiltration of toxic agents and inflam-
matory cells.
The most important challenge for the future in this field will be
to develop suitable and sensitive imaging tools to study the orga-
nization of adherens junctions and their assembly and disas-
sembly in vivo in the different vascular beds and under different
pathophysiological conditions.ACKNOWLEDGMENTS
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